» Articles » PMID: 29276511

Generation and Functional Analysis of Semliki Forest Virus Vectors Encoding TNF-α and IFN-γ

Overview
Journal Front Immunol
Date 2017 Dec 26
PMID 29276511
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Cytokine gene delivery by viral vectors is a promising novel strategy for cancer immunotherapy. Semliki Forest virus (SFV) has many advantages as a delivery vector, including the ability to (i) induce p53-independent killing of tumor cells apoptosis, (ii) elicit a type-I interferon (IFN) response, and (iii) express high levels of the transgene. SFV vectors encoding cytokines such as interleukin (IL)-12 have shown promising therapeutic responses in experimental tumor models. Here, we developed two new recombinant SFV vectors encoding either murine tumor necrosis factor-α (TNF-α) or murine interferon-γ (IFN-γ), two cytokines with documented immunostimulatory and antitumor activity. The SFV vector showed high infection rate and cytotoxicity in mouse and human lung carcinoma cells . By contrast, mouse and human macrophages were resistant to infection with SFV. The recombinant SFV vectors directly inhibited mouse lung carcinoma cell growth , while exploiting the cancer cells for production of SFV vector-encoded cytokines. The functionality of SFV vector-derived TNF-α was confirmed through successful induction of cell death in TNF-α-sensitive fibroblasts in a concentration-dependent manner. SFV vector-derived IFN-γ activated macrophages toward a tumoricidal phenotype leading to suppressed Lewis lung carcinoma cell growth in a concentration-dependent manner. The ability of SFV to provide functional cytokines and infect tumor cells but not macrophages suggests that SFV may be very useful for cancer immunotherapy employing tumor-infiltrating macrophages.

Citing Articles

Bacteria and RNA virus inactivation with a high-irradiance UV-A source.

Spunde K, Rudevica Z, Korotkaja K, Skudra A, Gudermanis R, Zajakina A Photochem Photobiol Sci. 2024; 23(10):1841-1856.

PMID: 39305443 DOI: 10.1007/s43630-024-00634-2.


Styrylpyridinium Derivatives for Fluorescent Cell Imaging.

Putralis R, Korotkaja K, Kaukulis M, Rudevica Z, Jansons J, Nilova O Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765053 PMC: 10535741. DOI: 10.3390/ph16091245.


Establishment and Characterization of Free-Floating 3D Macrophage Programming Model in the Presence of Cancer Cell Spheroids.

Korotkaja K, Jansons J, Spunde K, Rudevica Z, Zajakina A Int J Mol Sci. 2023; 24(13).

PMID: 37445941 PMC: 10341749. DOI: 10.3390/ijms241310763.


Recombinant Virus Quantification Using Single-Cell Droplet Digital PCR: A Method for Infectious Titer Quantification.

Korotkaja K, Zajakina A Viruses. 2023; 15(5).

PMID: 37243145 PMC: 10221717. DOI: 10.3390/v15051060.


Recombinant Viral Vectors for Therapeutic Programming of Tumour Microenvironment: Advantages and Limitations.

Spunde K, Korotkaja K, Zajakina A Biomedicines. 2022; 10(9).

PMID: 36140243 PMC: 9495732. DOI: 10.3390/biomedicines10092142.


References
1.
Haabeth O, Lorvik K, Yagita H, Bogen B, Corthay A . Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells. Oncoimmunology. 2016; 5(1):e1039763. PMC: 4760324. DOI: 10.1080/2162402X.2015.1039763. View

2.
Singh M, Khong H, Dai Z, Huang X, Wargo J, Cooper Z . Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol. 2014; 193(9):4722-31. PMC: 4201984. DOI: 10.4049/jimmunol.1401160. View

3.
Laster S, Wood J, Gooding L . Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol. 1988; 141(8):2629-34. View

4.
Zajakina A, Kozlovska T, Bruvere R, Aleksejeva J, Pumpens P, Garoff H . Translation of hepatitis B virus (HBV) surface proteins from the HBV pregenome and precore RNAs in Semliki Forest virus-driven expression. J Gen Virol. 2004; 85(Pt 11):3343-3351. DOI: 10.1099/vir.0.80388-0. View

5.
Davies J, Gordon S . Isolation and culture of murine macrophages. Methods Mol Biol. 2004; 290:91-103. DOI: 10.1385/1-59259-838-2:091. View